Welcome to our dedicated page for Foghorn Therapeutics news (Ticker: FHTX), a resource for investors and traders seeking the latest updates and insights on Foghorn Therapeutics stock.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) generates news as a clinical-stage biotechnology company focused on oncology medicines that target genetically determined dependencies within the chromatin regulatory system. Its updates frequently highlight progress from the Gene Traffic Control® platform, which systematically identifies and validates chromatin-based targets for small-molecule inhibitors and protein degraders.
News about FHTX often centers on its lead clinical candidate FHD-909 (LY4050784), a first-in-class oral SMARCA2 selective inhibitor being evaluated in a Phase 1 multi-center dose-escalation trial for SMARCA4-mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population. Press releases describe preclinical data, trial enrollment status, and combination strategies with standard-of-care chemotherapies, pembrolizumab, and KRAS inhibitors in NSCLC models.
Investors following FHTX can also expect regular announcements on Foghorn’s selective degrader programs. These include a selective CBP degrader with potential in EP300-mutant cancers and ER+ breast cancer, a selective EP300 degrader for hematologic malignancies such as multiple myeloma and diffuse large B-cell lymphoma, and a selective ARID1B degrader for ARID1A-mutated solid tumors. Company communications summarize preclinical efficacy, tolerability, and formulation advances, as well as milestones such as progression into toxicology or IND-enabling studies.
Another recurring theme in Foghorn’s news flow is corporate and financial activity. Releases discuss collaboration revenue from its strategic partnership with Lilly, cash and marketable securities levels, and equity financings conducted under a shelf registration statement on Form S-3, including a registered direct financing that raised approximately $50 million in gross proceeds. Updates on leadership changes in the finance function and participation in healthcare and investor conferences also appear in FHTX news.
By monitoring this news page, readers can review company-issued information on trial progress, preclinical data, financing transactions, collaborations, and corporate developments that shape the ongoing story of Foghorn Therapeutics’ chromatin-focused oncology pipeline.
Flagship Pioneering, a bioplatform innovation company, announced it has raised $3.6 billion to foster the growth of 25 groundbreaking companies in human health, sustainability, and AI. This includes $2.6 billion into Fund VIII and $1 billion from sector-specific partnerships, bringing the total capital raised since 2021 to $6.4 billion. The company now operates with an aggregate capital pool of $10.9 billion and manages $14 billion in assets.
Flagship's recent partnerships include collaborations with Pfizer, Samsung, Thermo Fisher Scientific, and Novo Nordisk. These alliances are part of Flagship's Innovation Supply Chain Partnership (ISC) model, which maximizes innovation across various stages of product development.
The company has expanded globally, establishing hubs in London and Singapore to enhance its R&D collaborations and access international talent. Flagship has also bolstered its leadership team with several key hires and promotions to drive its growth and innovation strategy.
Flagship Pioneering, a bioplatform innovation company, has expanded its leadership team with new appointments and promotions. These changes accompany an expanded capital base of $3.6 billion for the development of 25 breakthrough platform companies in human health, sustainability, and AI.
Key promotions include Lovisa Afzelius to General Partner, Paul Biondi to General Partner, Dina Ciarimboli as General Counsel, Marcello Damiani as Senior Partner, Gary Pisano as Chief Strategist, and other critical roles filled by experienced professionals. These leaders bring significant expertise from major firms like Pfizer, Bristol-Myers Squibb, Moderna, and Harvard Business School.
Flagship aims to leverage these appointments to drive innovation, enhance strategic partnerships, and improve operational efficiency across its ecosystem of companies, furthering its mission to pioneer transformative technologies.
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on treating serious diseases by correcting abnormal gene expression, announced its participation in two major investor conferences in June 2024. The Jefferies Global Healthcare Conference will feature Adrian Gottschalk, CEO, presenting on June 5, 2024, at 3:30 p.m. ET in New York. The Goldman Sachs 45th Annual Global Healthcare Conference will also include a presentation by Gottschalk on June 10, 2024, at 3:20 p.m. ET in Miami Beach. Both presentations will be accessible via webcast for 30 days on the company's website.
Foghorn Therapeutics has successfully closed a registered direct offering, raising approximately $110 million. This funding will bolster the company’s platform and advance its diverse pipeline of treatments for diseases, especially in oncology. The offering, which includes new and existing investors like BVF Partners and Flagship Pioneering, strengthens Foghorn's balance sheet, extending its cash runway into 2027. With $310 million in cash, cash equivalents, and short-term investments, the company is well-positioned for upcoming data readouts and clinical milestones. The offering priced 12,743,039 common shares at $5.51 each, and pre-funded warrants to buy 7,220,794 shares at $5.5099 each.
Foghorn Therapeutics (FHTX) has announced a registered direct offering of 12,743,039 shares of its common stock at $5.51 per share and pre-funded warrants for 7,220,794 shares at $5.5099 per warrant. This offering aims to raise approximately $110 million in gross proceeds. The closing is expected around May 22, 2024, pending customary conditions. Proceeds will be used for advancing preclinical and clinical programs and general corporate purposes. Jefferies, TD Cowen, and Evercore ISI are managing the offering. The securities are offered pursuant to an effective shelf registration statement filed with the SEC.
Foghorn Therapeutics Inc. provided a financial and corporate update for Q1 2024. The company showcased strong preclinical anti-tumor activity in multiple pipeline programs and progress in AML and NSCLC studies, with data expected in the second half of 2024. IND filing for a first-in-class oral BRM inhibitor was submitted, along with updates on selective CBP and EP300 degrader programs. The company presented promising data at AACR, appointed a new CFO, and reported cash reserves of $206.7 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.